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Homocysteine can be remethylated through the major folic cycle path. It is recycled to methionine in a reaction catalyzed by
the enzyme methionine synthase and is absolutely dependent on the essential vitamin B12 methylcobalamin (MeCbl). All other
forms of vitamin B12 must be converted to MeCbl prior to their usage(1). This can prove to be problematic, particularly for the
aged(2,3). Vegetarians are known to be susceptible to vitamin B12 deﬁciency, due to a lack of dietary animal produce, which can ele-
vate plasma total homocysteine (tHcy). There is positive evidence that links elevated plasma (tHcy) with cardiovascular disease
(CVD)(4).
The speciﬁc objective of the present study was to establish if supplementary MeCbl will optimise elevated levels of plasma tHcy of
vitamin B12 deﬁcient vegetarians.
The design of the study was a parallel double blind randomised placebo controlled trial. The treatment regimes were either a 1 mg
MeCbl lozenge (the intervention group) taken every second day for 16 weeks or identical placebo. Successful participants ﬁrstly
completed a conﬁdential questionnaire/application form and met the study criteria, which included having a baseline plasma tHcy
level > 10 μmolL−1 and who had been practicing vegetarianism for ⩾ 3 years, age 18 to 65 years old were recruited via the
Vegetarian and Vegan Societies. The subjects comprised lactovegetarians/ lactoovovegetarians (n = 25) and vegans (n = 14).
During the study participant diets were closely supervised by the compilation of diet diaries. Homocysteine assay was conducted
by the accredited and validated self-test kit supplied and tested by Yorktest Laboratories Ltd. The study was approved by the
University Ethics Committee and conducted in accordance with the WMA declaration of Helsinki. The protocol for the study
was registered with ClinicalTrials.gov Protocol Registration System. A paired samples t test on baseline and post intervention levels
of plasma t Hcy was performed employing SPSS software, with the null hypothesis (H0) being deﬁned as ‘there will be no reduction in
plasma tHcy following treatment’ H0 was rejected if the change in plasma tHcy was not zero, but accepted if it was zero. The results
are summarised below:
The results indicates that H0 can be rejected for the MeCbl group since P< 0·05 and CI 95 % does not pass through zero whereas
the placebo group H0 is accepted, since P > 0·05 and CI 95 % passes through zero. The paired samples t test also demonstrated that
MeCbl effectively optimised homocysteine levels of baseline mean value of 15·5μmolL−1 to post intervention mean level of
8·4μmolL−1 (not shown).
Examination of participant food diaries conﬁrmed that strict vegetarian diets were maintained throughout the period of the study
and that all other bio-regulation of homocysteine nutrients met RDA and AI values. Overall, it is therefore reasonable to deduce that
the results of the study indicate that MeCbl optimises elevated levels of homocysteine (to <10μmolL−1) of vitamin B12 deﬁcient vege-
tarians and will potentially reduce the risk of CVD together with providing data to perform a (probable ﬁrst) deﬁnitive clinical trial.
These ﬁndings will also potentially inform the dietary advice given to vegetarians.
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Lozenge type n df P (2-tailed) Mean difference 95 % conﬁdence interval
(α = 0.05) (μmolL−1) (μmolL−1)
Methylcobalamin 20 19 0.00 −7.1 (−9.35. −4.85)
Placebo 19 18 0.16 −1.1 (−2.70, 0.48)
Test value = 0.
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